Stay updated on Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial

Sign up to get notified when there's something new on the Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error, replacing the study content and navigation with a standard error page. This blocks access to the study details.
    Difference
    19%
    Check dated 2026-09-20T20:34:17.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    33 days ago
    Change Detected
    Summary
    A new NIH grant/contract funding note was added to the study identifiers, and the page revision was updated to v3.6.6 (replacing v3.6.5).
    Difference
    0.1%
    Check dated 2026-08-30T15:43:51.000Z thumbnail image
  5. Check
    55 days ago
    Change Detected
    Summary
    Revision: v3.6.5 added to the page. A large set of older study document entries (e.g., SAPs, Study Protocol, and related items) were removed from the Study Documents section, reflecting cleanup rather than new trial data.
    Difference
    17%
    Check dated 2026-08-08T23:26:29.000Z thumbnail image
  6. Check
    70 days ago
    Change Detected
    Summary
    Revision updated from v3.6.3 to v3.6.4, reflecting a small internal update to the page rendering. No visible study details or user-facing content were changed.
    Difference
    0.0%
    Check dated 2026-07-25T13:25:44.000Z thumbnail image
  7. Check
    91 days ago
    Change Detected
    Summary
    The page footer now displays Revision: v3.6.3, indicating a minor platform/template update for the study record page.
    Difference
    0.0%
    Check dated 2026-07-03T23:23:43.000Z thumbnail image
  8. Check
    98 days ago
    Change Detected
    Summary
    The page's revision was updated from v3.6.0 to v3.6.2, signaling a backend/frontend update to the listing without modifying the study information.
    Difference
    0.0%
    Check dated 2026-06-27T00:12:46.000Z thumbnail image

Stay in the know with updates to Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial page.